Ying Xue

Dr. Ying Xue

Auto-generated profile, based on publicly available information

Dr. Ying Xue


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
BJBeihong Ji
Beihong Ji
SLShuhan Liu
Shuhan Liu
YXYing Xue
Ying Xue
XHXibing He
Xibing He
VMViet Hoang Man
Viet Hoang Man
Junmei WangJunmei Wang
Junmei Wang
Background Researchers have long been interested in the potential drug–drug interactions (DDIs) between opioids and benzodiazepines. However, much remains unknown concerning the interactions between these two drug classes. The objective of this work is to study the mechanism underlying the DDIs between opioids and benzodiazepines from the perspective of their pharmacokinetic (PK) interactions. A PK interaction occurs when two drugs are metabolized by the same cytochrome P450 enzymes and is one of the most common reasons for DDIs. Methods We quantitatively predicted the DDIs between three opioids (fentanyl, oxycodone and buprenorphine) and four benzodiazepines (alprazolam, diazepam, midazolam and triazolam) using a physiologically based pharmacokinetic (PBPK) modeling approach. A set of PBPK models was first constructed for these common opioids and benzodiazepines using SimCYP software, and the DDIs between them were then explored at various dosages. Results Our simulation results suggested there were no PK interactions between normal doses of opioids and benzodiazepines; but weak interactions can be expected with the combination of opioids and overdosed benzodiazepines. Particular attention should be given to the combination of fentanyl and overdosed alprazolam since a PK interaction can be observed between them. Conclusion Our results appear to indicate that pharmacodynamics may play a more important role than PKs in causing DDIs between opioids and benzodiazepines. This study also demonstrated that molecular modeling can be a very useful tool to mitigate the problem of “missing metabolic reaction parameters” in PK modeling and simulation.

30 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
YXYing Xue
Ying Xue
XXXiang-Qun Xie
Xiang-Qun Xie
This study explores the potential impact of metformin on the development of severe dementia in individuals with Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). With an emerging interest in the role of the APOE genotype in mediating metformin’s effects on cognitive decline in AD patients, we sought to investigate whether metformin usage is associated with a reduced risk of severe dementia. Using data from the National Alzheimer’s Coordinating Center (NACC) database (2005–2021), we identified 1306 participants with both AD and T2DM on diabetes medications. These individuals were categorized based on metformin usage, and a propensity score-matched cohort of 1042 participants was analyzed. Over an average follow-up of 3.6 years, 93 cases of severe dementia were observed. A Kaplan–Meier analysis revealed that metformin users and non-users had similar probabilities of remaining severe dementia-free (log-rank p = 0.56). Cox proportional hazards models adjusted for covariates showed no significant association between metformin usage and a lower risk of severe dementia (HR, 0.96; 95% CI, 0.63–1.46; p = 0.85). A subgroup analysis based on APOE ε4 carrier status demonstrated consistent results, with metformin use not correlating with a reduced severe dementia risk. In conclusion, our findings from a substantial cohort of AD and T2DM patients suggest that metformin usage is not significantly associated with a decreased risk of severe dementia. This observation persists across APOE ε4 carriers and non-carriers, indicating a lack of genotype-mediated effect.

1 January 2025 in Research
Verified
Journal Article
Open access
TLTianjian Liang
Tianjian Liang
ZSZe-Yu Sun
Ze-Yu Sun
RIRieko Ishima
Rieko Ishima
XXXiang-Qun Xie
Xiang-Qun Xie
YXYing Xue
Ying Xue
ZFZHIWEI FENG
ZHIWEI FENG
Proteins play a critical role in biology and biopharma due to their specificity and minimal side effects. Predicting the effects of mutations on protein stability is vital but experimentally challenging. Deep learning offers an efficient solution to this problem. In the present work, we introduced ProstaNet, a deep learning framework that predicts stability changes resulting from single- and multiple-point mutations using geometric vector perceptrons–graph neural network for 3-dimensional feature processing. For training ProstaNet, we meticulously crafted ProstaDB, a comprehensive and pristine thermodynamics repository, including 3,784 single-point mutations and 1,642 multiple-point mutations. We also created thermodynamic looping for enlarging the limited data size of multiple-point mutation and applied an innovative clustering method to generate a standard testing set of multiple-point mutation. Besides, we identified residue scoring as the most important encoding method in protein properties prediction. With these innovations, ProstaNet accurately predicts thermostability changes for both single-point and multiple-point mutations without showing any bias. ProstaNet achieves an accuracy of 0.75, outperforming existing methods for single-point mutation prediction, including ThermoMPNN (0.63), PoPMuSiC sym (0.66), MUPRO (0.52), and FoldX (0.71). ProstaNet also achieves a 1.3-fold increase in accuracy compared to FoldX for multiple-point mutation predictions. Validated by experiment, 4 out of 5 single-point mutation predictions (80%) and all multiple-point mutation predictions (100%) for HuJ3 mutants were accurate, demonstrating the potential benefits of ProstaNet for protein engineering and drug development.

3 April 2025 in The AAPS Journal
Verified
Journal Article
Closed access
YJYankang Jing
Yankang Jing
GZGuangyi Zhao
Guangyi Zhao
YXYuanyuan Xu
Yuanyuan Xu
TMTerence McGuire
Terence McGuire
GHGanqian Hou
Ganqian Hou
XXXiang-Qun Xie
Xiang-Qun Xie

27 June 2025 in Advanced Science
Verified
Journal Article
Open access
ZSZe‐Yu Sun
Ze‐Yu Sun
JYJiayi Yuan
Jiayi Yuan
DJDivya Jaiswal
Divya Jaiswal
JGJingxuan Ge
Jingxuan Ge
TLTianjian Liang
Tianjian Liang
ZFZhiwei Feng
Zhiwei Feng
Antibodies are crucial for medical applications, yet traditional methods for designing sequences are inefficient. This study introduces AntiBMPNN, an advanced deep‐learning framework that leverages an antibody‐specific 3D dataset, a fine‐tuned message‐passing neural network (MPNN), a frequency‐based scoring function, and AlphaFold 3 to achieve highly accurate antibody sequence design. AntiBMPNN surpasses ProteinMPNN with a perplexity of 1.5 and over 80% sequence recovery. Its scoring function, combined with AlphaFold 3, effectively prioritizes sequences based on structural recovery, positional stability, and biochemical or complex properties. Experimental validation highlights a 75% success rate in single‐point antibody design. AntiBMPNN consistently outperforms AbMPNN, AntiFold, and ProteinMPNN in designing complementarity determining regions (CDR) 1‐3, yielding stronger binding affinities. For CDR1 of huJ3 (anti‐HIV nanobody), it achieves a half maximal effective concentration (EC₅₀) of 9.2 nM (nanomolar), better than ProteinMPNN (135.2 nM) and AntiFold (59.3 nM), and comparable to AbMPNN (6.6 nM). For CDR2 of the D6 nanobody (targeting CD16), AntiBMPNN reaches 0.3 nM, outperforming AbMPNN (2.3 nM), AntiFold (0.7 nM), and ProteinMPNN (0.7 nM). In CDR3 of huJ3, it achieves 1.7 nM, surpassing AbMPNN (51.2 nM), with no detectable activity from AntiFold or ProteinMPNN. These findings confirm that AntiBMPNN‐designed sequences for J3 and D6 outperform the originals, highlighting its potential to improve therapeutic antibody design.

1 April 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
YXYing Xue
Ying Xue
ZWZi Wang
Zi Wang
HWHongyi Wu
Hongyi Wu
XLXiaoye Li
Xiaoye Li
JCJiahui Chen
Jiahui Chen
QLQianZhou Lv
QianZhou Lv
What is Known and Objective Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels. The clinical benefit of cilostazol in ACS patients suggested that the drug may have non-platelet-directed properties. Some in vitro and animal studies also indicated that the 'pleiotropic' properties of cilostazol might be related to the interaction with adenosine metabolism. Adenosine is an important regulatory metabolite and an inhibitor of platelet activation. However, no human study has been conducted to determine whether cilostazol could increase the adenosine plasma concentration in vivo. As a result, this study aimed to investigate the impact of cilostazol on adenosine plasma concentration (APC) in acute coronary syndrome (ACS) patients. Methods We prospectively analysed 149 ACS patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents. The included patients were divided into two groups according to the presence (cilostazol group, n = 64) or absence (aspirin group, n = 85) of aspirin intolerance. The inhibition of platelet aggregation (IPA), APC and cAMP concentration was measured. Patient characteristics, medications and 30-day clinical outcomes were examined. Results Patients receiving cilostazol had a significantly higher adenosine and cAMP plasma concentration than patients receiving aspirin (3.00 +/- 0.67 vs 2.56 +/- 0.74 mol/L,P < .001; 28.10 +/- 14.74 vs 20.48 +/- 11.35 pmol/mL,P = .0014). Cilostazol was associated with a higher inhibition rate of ADP induced platelet aggregation than aspirin (63.35 +/- 26.71 vs 52.2 +/- 28.35,P = .036). The plasma levels of adenosine and cAMP showed a positive correlation with ADP induced platelet aggregation. What is New and Conclusion Cilostazol increases adenosine concentration compared with aspirin. Its potent antiplatelet effect in ACS patients may be partly mediated by adenosine.